with an IC 50 of 1,750 ng/ml, but was not effective in ISO-HAS. Everolimus reduced both ASM and ISO-HAS viable cell counts by 20 % (p < 0.001). Minimal responses were observed to bevacizumab and axitinib in assays with ASM and ISO-HAS cells. Conclusions Further studies are warranted to investigate mTOR inhibitors, MEK inhibitors and vascular-disrupting agents for the treatment of angiosarcoma.
Introduction
Angiosarcomas are rare aggressive vascular tumours of malignant endothelial cells and are associated with a poor prognosis [1] . Despite radical treatment with surgery and adjuvant radiotherapy for localised disease, tumour recurrence and metastatic spread are common. Single agent doxorubicin or paclitaxel chemotherapy is recommended for the treatment of advanced disease [2] , but relapse and death are inevitable. Alternative therapeutic options are therefore required.
Angiogenesis is the process of new blood vessel formation from the existing vasculature [3] . In response to proangiogenic growth factors secreted by tumours, endothelial cells from the established vasculature proliferate, migrate and invade. A variety of growth factors initiate angiogenesis, of which vascular endothelial growth factor (VEGF) is the most potent identified to date [4] . Several small immunohistochemistry studies have identified increased expression of VEGF and its receptors (VEGFR1-3) in human angiosarcomas relative to benign vascular lesions [5] [6] [7] [8] [9] . A previous molecular study of 22 angiosarcoma tumour Abstract Purpose Angiosarcomas are rare, aggressive vascular tumours known to express vascular endothelial growth factor (VEGF), a key pro-angiogenic growth factor. The aim of this study was to determine the potential effects of vascular-targeted agents for the treatment of angiosarcoma, using two human cutaneous angiosarcoma cell lines (ASM and ISO-HAS), and human dermal microvascular endothelial cells (HuDMECs) for comparison. Methods Protein arrays were used to assess the expression of angiogenesis-related proteins, and potential drug targets were assessed by ELISA and Western blotting. Response to vascular-targeted agents, including bevacizumab an anti-VEGF antibody, axitinib a VEGF-receptor tyrosine kinase inhibitor, everolimus an mTOR inhibitor, selumetinib a MEK inhibitor and vadimezan a vasculardisrupting agent were compared in functional in vitro cellular assays, including viability, differentiation and migration assays. Results ASM and ISO-HAS cells expressed a broad range of pro-angiogenic growth factors. ASM and ISO-HAS VEGF expression was significantly increased (p = 0.029) compared with HuDMECs. Striking responses were seen to vadimezan with an IC 50 of 90 and 150 μg/ml for ASM and ISO-HAS cells, respectively. Selumetinib inhibited ASM 1 3 samples reported VEGFR2 mutations associated with autophosphorylation in four cases (18 %) [10] , in contrast no VEGFR2 mutations were identified in a larger study of 41 angiosarcoma tumour samples [11] .
It remains unclear whether VEGF expression is a cause or effect of the malignant endothelial cell proliferation observed in angiosarcoma. In pre-clinical studies, a murine endothelial cell line induced to overexpress VEGF formed well-differentiated angiosarcomas in vivo [12] . In contrast, small phase II clinical trials of tyrosine kinase inhibitors (TKIs) targeting VEGF receptors for the treatment of advanced angiosarcoma have reported modest response rates of only 10-14 % [11, 13, 14] . Similarly, a phase II study of bevacizumab, a monoclonal anti-VEGF antibody, reported an angiosarcoma response rate of 12 % [15] . Angiosarcoma responses to other classes of targeted agents such as PI3K/Akt/mTOR pathway inhibitors, MEK inhibitors and vascular-disrupting agents have not been reported and represent potential alternative therapeutic approaches.
As angiosarcomas are rare (1 % of soft tissue sarcomas), bio-repositories have very limited numbers of tumour samples, thus there are few published molecular studies of angiosarcoma. Tumour models are needed and of great importance for studying angiosarcoma biology, identifying new drug targets and determining the response to novel agents. Currently however, there are no established pre-clinical models of angiosarcoma. ASM and ISO-HAS are two human tumour cell lines derived from samples collected from patients with advanced cutaneous angiosarcoma of the scalp; ASM was developed by KrumpKonvalinkova et al. [16] , and ISO-HAS by Masuzawa et al. [17] . Consistent with an endothelial phenotype, both ASM and ISO-HAS cells uptake Dil-Ac-LDL and express CD31, vWF and VEGFR1 and 2 [16] [17] [18] . To date however, neither ASM nor ISO-HAS have been systematically studied as potential models of human angiosarcoma, and we therefore selected these cell lines for in vitro study.
As angiosarcomas are malignant tumours of endothelial origin, we hypothesised that angiogenic growth factors would influence tumour cell growth and represent potential therapeutic targets. A series of studies were performed with ASM and ISO-HAS cell lines, profiling angiogenesis-related protein expression, and investigating in vitro responses to vascular-targeted agents, using human dermal microvascular endothelial cells (HuDMECs) as a nonmalignant control.
Baseline studies were performed to assess ASM and ISO-HAS response to chemotherapeutic agents, and functional in vitro assays were then used to evaluate responses to the anti-VEGF antibody bevacizumab and the VEGFR TKI axitinib at clinically relevant doses [19, 20] . Bevacizumab is a humanised monoclonal antibody to VEGF that binds circulating VEGF to prevent the stimulation of VEGF receptors [21] . Axitinib is a tyrosine kinase inhibitor, and a potent inhibitor of the VEGF receptors, with an IC 50 of 0.1-0.3 nmol/l [22] . Axitinib also inhibits PDGFRs and KIT in nanomolar concentrations and is a weak inhibitor of FGFR1. Axitinib is currently under investigation in a clinical phase II study in advanced angiosarcoma and other soft tissue sarcomas (Axi-STS; ISRCTN 60791336).
In addition, we studied in vitro responses to the mTOR inhibitor everolimus, the MEK inhibitor selumetinib and the vascular-disrupting agent vadimezan at clinically relevant doses [23] [24] [25] . Everolimus is an mTOR inhibitor that reduces VEGF expression by reducing the synthesis of HIF-1α [26] . mTOR inhibition has broader cellular effects beyond reducing the expression of VEGF, including decreased protein synthesis and reduced cell growth [26] . Selumetinib is a selective inhibitor of MEK1/2 that phosphorylates and activates ERK. Vadimezan is a flavonic acid derivative vascular-disrupting agent that reduces tumour blood flow and induces tumour necrosis. Vadimezan's anti-tumour properties are not fully understood. Within 15 min of in vivo administration, vadimezan induces apoptosis of tumour endothelial cells leading to reduction in tumour blood flow [27] . Endothelial cell death exposes the underlying basement membrane that induces platelet activation and leads to a localised increase in 5-HIAA (5-hydroxyindole-3-acetic acid), resulting in vascular constriction and thus tumour hypoxia and necrosis [28] . Through activation of nuclear factor kappa B (NF-κB), vadimezan induces tumour production of a number of cytokines including TNFα [28] that appears important for mediating tumour response to vadimezan, with treatment less effective in TNF receptor-1 knockout mice [29] .
Materials and methods

Cells and cell culture
The ASM cell line was kindly provided by Professor V Krump-Konvalinkova, Institute of Pathology, Johannes Gutenburg University Mainz, Germany. The ISO-HAS cell line was kindly provided by Professor M Masuzawa, Cell Resource Centre for the Biomedical Research Institute of Development, Aging and Cancer, Tohoku University, Japan. ASM and ISO-HAS cells were cultured in endothelial cell growth media MV (ECGM MV) (PromoCell), plus ECGM supplement mix (PromoCell), 10 % foetal calf serum (FCS) (Gibco), 0.5 % penicillin, 0.5 % streptomycin and 0.5 % amphotericin. HuDMECs (PromoCell) were used as controls, as a non-malignant endothelial cell line and grown in ECGM MV plus supplement mix. Experiments with ASM and ISO-HAS cells were performed using cell passages 3-20 and with HuDMECs using cell passages 3-6. Both angiosarcoma cell lines demonstrated endothelial morphology in culture, and initial studies were performed that confirmed ASM, ISO-HAS and HuDMEC cells absorbed Dil-Ac-LDL and expressed CD31, vWF and VEGFR1 and 2 consistent with their endothelial phenotype (data not shown).
Protein array studies
The expression of 55 angiogenesis-related proteins were compared in ASM, ISO-HAS and HuDMEC cell lysates using Proteome Profiler Antibody Arrays (R&D Systems ARY007). Arrays were performed according to manufacturer's instructions. Duplicate antibody spot peak densities were measured using a GS-710 Calibrated Imaging Densitometer (Bio-Rad) and Quantity One (version 4.6.8) 1-D image analysis software and averaged. Density readings were adjusted relative to an internal positive control and background reading. Protein array studies were repeated twice using separate cell samples and the results averaged.
VEGF ELISA studies T75 flasks of semi-confluent cells were washed in PBS and starved overnight in 10mls EBM-2 media (Lonza) with 1 % FCS. Cell lysates were prepared on ice, and the cell supernatant was collected, filtered (0.2 μm) and stored at −80 °C until use. As VEGF expression is induced by hypoxia, cell lysates were also prepared from cells starved overnight in hypoxic conditions (1 % O 2 ). VEGFA enzymelinked immunosorbent assay (ELISA) (R&D Systems) was performed according to manufacturer's instructions. VEGFA concentrations were measured in duplicate wells from samples collected on three independent occasions, and the result averaged. VEGFA concentration in the cell supernatant was expressed relative to the total protein concentration in the cell lysates.
Pharmacological agents
Paclitaxel (Sigma-Aldrich), doxorubicin (Sigma-Aldrich), bevacizumab (Roche), everolimus (Selleck), selumetinib (Selleck) and vadimezan (Santa Cruz) were purchased. Axitinib was provided by Pfizer. Drugs were dissolved in dimethyl sulfoxide (DMSO) except for bevacizumab. A control vehicle for bevacizumab was prepared from 51 mM sodium phosphate, 60 mg/ml trehalose dehydrate and 0.04 % polysorbate 20 at pH 6.2 [30] . DMSO or bevacizumab control vehicle were added to wells to ensure an equal concentration throughout.
Cell viability assay 100,000 viable ASM or ISO-HAS cells per 1 ml media were seeded in each well of a 12-well plate. After 48 h, drug concentrations of paclitaxel 0-25 ng/ml, doxorubicin 0-25 ng/ml, bevacizumab 0.25 mg/ml, axitinib 0-250 ng/ ml, everolimus 0-250 ng/ml, selumetinib 0-2,000 ng/ml or vadimezan 0-300 μg/ml were added. Cell proliferation was then assessed 120 h later with a semi-automated Beckman Coulter Vi-CELL using trypan blue to assess viability. Drug concentrations were assessed in triplicate wells, and each experiment was repeated at least three times. Dose responses were plotted, and the half maximal inhibitory concentration (IC 50 ) estimated from the line of best fit.
Cell differentiation (tubule formation) assay ASM, ISO-HAS and HuDMEC cells were starved overnight in EBM-2 media, 1 % FCS. 40 μls of growth factor-reduced basement membrane extract (Matrigel; BD Biosciences) were added to wells of a 96-well plate. Ten thousand cells in 100 μl media were added in the presence or absence of recombinant VEGF 165 (rVEGF) 50 ng/ml (R&D Systems), with bevacizumab 0.25 mg/ml, axitinib 0-250 ng/ml, selumetinib 0-2,000 ng/ml or vadimezan 0-100 μg/ml. Tubule formation was assessed after 6 h; wells were photographed and the total number of tubules in each well counted manually. Drug concentrations were assessed in triplicate wells and experiments were repeated at least three times.
Migration assay
Cell migration was assessed using a Boyden chamber. ASM, ISO-HAS and HuDMEC cells were starved overnight in EBM-2 media, 1 % FCS. The dividing polycarbonate porous membrane (8 μm pores) (NeuroProbe) was coated in collagen IV (Sigma-Aldrich). 30 μl of media and axitinib 0-250 ng/ml or bevacizumab 0.25 mg/ml, with or without rVEGF 20 ng/ml, were added to lower chambers. 15,000 cells in 50 μl of media with an equivalent concentration of axitinib or bevacizumab were added to upper chambers. The Boyden chamber was then incubated at 37 °C for 4 h before the dividing membrane was removed, fixed in methanol, and cells stained with haematoxylin. Cells migrated through to the underside of the porous membrane were counted manually at 20× magnification. A migration count was calculated for each condition from triplicate wells, and experiments were repeated at least three times.
Western blotting
Semi-confluent T75 flasks of ASM, ISO-HAS and HuD-MEC cells were starved overnight in EBM-2 media and 1 % FCS. Bevacizumab 0.25 mg/ml or axitinib 0-250 ng/ ml were added for 1 h, and rVEGF 50 ng/ml then added for 3 min. Cell lysates were formed on ice by the addition of lysis buffer containing phosphatase and protease inhibitor cocktails (Roche). Equal protein amounts were assessed. Membranes were probed with rabbit anti-VEGFR2 and rabbit anti-pVEGFR2 (Tyrosine-1175) antibodies (Cell Signalling Technology). 5 % milk was used as blocking agent with anti-VEGFR2 antibody. Membranes were blocked for 1 h at room temperature and then incubated with the primary antibody (1:1,000) overnight at 4 °C. PBST 0.1 % was used for membrane washes. 5 % bovine serum albumin (BSA) was used as the blocking agent when probing for pVEGFR2. Membranes were blocked overnight at 4 °C and then incubated with primary antibody (1:1,000) at room temperature for 2 h. Membranes were washed in TBST 0.1 %. ECL antirabbit horseradish peroxidise-linked whole antibody (GE Healthcare) was used as the secondary antibody (1:3,000) and incubated for 1 h at room temperature before chemiluminescent reagent (Millipore) was added, and the membranes imaged. VEGFR2 western blot studies were repeated at least twice.
The effect of axitinib 0-250 ng/ml and bevacizumab 0.25 mg/ml on pERK expression in ASM and ISO-HAS cells was also investigated. Semi-confluent T75 flasks of cells were starved overnight in EBM-2, 1 % FCS. VEGFtargeted agents were added for 1 h and separate flasks of cells lysed 0, 5, 10 and 20 min after the addition of rVEGF 50 ng/ml. Lysates were generated as described above. 5 % milk was used as blocking agent. Membranes were incubated for 1 h at room temperature in blocking solution and then overnight at 4 °C with mouse antibody to pERK (Sigma-Aldrich) (1:10,000). Membranes were washed in PBST 0.1 % and then incubated at room temperature with secondary antibody (1:15,000) for 1 h. Following imaging, these membranes were stripped and re-probed with antibody to β-actin to demonstrate equivalent protein loading. Protein bands were quantified using a GS-710 Callibrated Imaging Densitometer (Bio-Rad) and Quality One (version 4.6.8) 1-D image analysis software. ERK western blot studies were performed twice.
Cell death
Following demonstration of cell responses to vadimezan in functional assays, the mechanisms inducing cell death were investigated using flow cytometry. The proportions of apoptotic and necrotic cells were measured in ASM cells incubated in full growth media ± vadimezan 100 μg/ml at 1, 4 and 12 h. Incubated cells were gently trypsinised, washed twice and re-suspended in Annexin V binding buffer at a concentration of 1×10 6 cells/ml. 100 μl of cell suspension were incubated with 5 μl of Alexa Fluor 647 Annexin V (BioLegend) for 15 min at room temperature in the dark. 400 μl of binding buffer and 10 μl of propidium iodide solution were added, and the sample was analysed by flow cytometry [BD LSR II analyser and BD FACS Diva Software (version 6.0)], on three independent repeats.
TNFα ELISA studies T175 flasks of ASM cells were incubated in full growth media ± vadimezan 100 μl/ml for 4 or 24 h. Cell lysates were formed on ice, and TNFα expression quantified by ELISA (R&D Systems) according to manufacturer's instructions. TNFα concentrations were measured in duplicate wells from samples collected on four independent occasions, and the result averaged.
Statistics
Statistical analysis was performed using SPSS 16.0 for Windows. Comparisons of protein array data between cell lines were performed using One-way ANOVA, with Tukey's range test for post hoc comparisons. VEGF secretion data were normally distributed and therefore compared using the independent t test. Drug responses were compared using the paired t test. Data were considered statistically significant at the level of p ≤ 0.05.
Results
Protein studies
The protein array studies demonstrated that ASM, ISO-HAS and HuDMEC cells expressed a wide range of angiogenesis-related proteins, with both tumour cell lines expressing increased angiogenin, coagulation factor III, FGF1, FGF2, HGF, uPA and VEGF, and decreased Ang-2 and MCP-1, relative to HuDMEC cells (Fig. 1) . Only VEGF expression was significantly elevated in both ASM and ISO-HAS cells when compared with HuDMECs (F(2,3) = 14.53, p = 0.029).
ELISA confirmed increased VEGF secretion in ASM and ISO-HAS cell supernatants compared with HuDMECs [mean ± SEM VEGF pg/ml HuDMEC vs ISO-HAS vs ASM cells, 23.8 ± 9.0 vs 149.9 ± 57.5 vs 179.5 ± 58.1 (p = 0.07 and 0.038, respectively)]. VEGF secretion increased in hypoxic conditions in both ASM and ISO-HAS supernatants when compared with HuDMECs [mean ± SEM VEGF pg/ml HuDMEC vs ISO-HAS vs 1 3 ASM cells, 64.9 ± 31.9 vs 829.4 ± 176.0 vs 855.5 ± 309.0 (p = 0.005 and 0.044, respectively)].
Chemotherapeutic agents
As chemotherapeutic agents recommended for the treatment of advanced angiosarcoma, baseline studies were performed to evaluate ASM and ISO-HAS responses to paclitaxel 0-25 ng/ml and doxorubicin 0-25 ng/ml chemotherapy in cell viability assays (Fig. 2a, b) . Striking responses were observed in both agents with an IC 50 for paclitaxel and doxorubicin of 10 ng and 20 ng/ml, respectively, in both angiosarcoma cell lines.
As HuDMEC cells are sensitive to tissue culture conditions and did not thrive in the cell viability assay, ASM and ISO-HAS responses to targeted agents in cell viability assays were compared with their responses to the recommended chemotherapeutic agents.
VEGF-targeted agents: cell viability
The protein array studies supported the analysis of ASM and ISO-HAS cell responses to VEGF-targeted agents and responses to bevacizumab 0.25 mg/ml, axitinib 0-250 ng/ ml and everolimus 0-250 ng/ml were evaluated. In contrast to the responses observed in cell viability assays with doxorubicin and paclitaxel, ASM and ISO-HAS cells did not respond to bevacizumab or axitinib, and an IC 50 was not reached (Fig. 2a, b) . Both ASM and ISO-HAS cells demonstrated a 20 % reduction in viable cell counts in response to treatment with 50 ng/ml everolimus (p < 0.001), which did not increase with increased drug concentrations (Fig. 2a, b) .
Combining chemotherapy with VEGF-targeted agents was also studied. Combination therapy of paclitaxel 5 ng/ml with either bevacizumab 0.25 mg/ml or axitinib 50 ng/ml was assessed, along with the combination of doxorubicin 10 ng/ ml with everolimus 50 ng/ml. The effects of combining therapies were additive, rather than synergistic (data not shown).
As only minimal ASM and ISO-HAS responses were observed to VEGF-targeted agents in cell viability assays, we decided to assess responses to bevacizumab and axitinib on cell differentiation and cell migration, representative of cellular functional assays. The cell differentiation assay, used to model angiogenesis in vitro, assessed endothelial tubule formation on Matrigel. Baseline studies compared the number of tubules formed per well of HuDMEC, ASM and ISO-HAS cells, 6 h after plating. Tubule morphology was very different between cell lines. HuDMECs formed an elegant network of tubules, whereas ISO-HAS formed numerous short tubules with ASM forming fewer and shorter tubules (Fig. 3a) . ISO-HAS and HuDMEC cells formed significantly more tubules than ASM cells [mean ± SEM number of tubules ASM vs ISO-HAS vs HuDMECs, 31 ± 9.5 vs 108 ± 17.2 vs 106 ± 11.7 (p = 0.006 and 0.008, respectively)].
The effects of the VEGF-targeted agents bevacizumab 0.25 mg/ml and axitinib 0-250 ng/ml were then studied on cell differentiation. The number of tubules formed by ASM and ISO-HAS cells did not differ significantly in response to bevacizumab 0.25 mg/ml (Fig. 3b) . The number of tubules formed by HuDMEC cells increased significantly in response to stimulation with rVEGF 50 ng/ml (p = 0.019), which was abrogated in the presence of bevacizumab 0.25 mg/ml (Fig. 3b) . (Fig. 3c) . However, at 50 ng/ml, axitinib significantly reduced the number of ISO-HAS tubules formed (p = 0.038) (Fig. 3c) . Fewer tubules were formed by HuDMEC cells in the presence of axitinib 50 ng/ml (p = 0.06) and 250 ng/ml (p = 0.07) compared with in the absence of axitinib, and significantly fewer HuDMEC tubules were formed in the presence of rVEGF with axitinib 250 ng/ml compared with rVEGF alone (p = 0.009) (Fig. 3c) .
VEGF-targeted agents: cell migration
The Boyden chamber was used to compare the migration of endothelial cells across a porous membrane. An increased number of ASM and ISO-HAS cells migrated was compared with HuDMECs [mean ± SEM migrated HuDMEC vs ASM vs ISO-HAS cells, 16.9 ± 1.9 vs 75.3 ± 7.4 vs 54.7 ± 6.7 (both p < 0.001)]. HuDMEC cell migration significantly increased in response to rVEGF 20 ng/ml [mean ± SEM HuDMEC cell migration in the absence and presence of rVEGF 20 ng/ml, 16.9 ± 1.9 vs 23.0 ± 1.5 (p = 0.011)], but ASM and ISO-HAS cell migration did not significantly differ [mean ± SEM ASM and ISO-HAS cell migration in the absence and presence of rVEGF 20 ng/ml, 75.3 ± 7.4 vs 77.3 ± 3.8 (p = 0.81) and 54.7 ± 6.7 vs 52.3 ± 5.1 (p = 0.39)].
The number of migrated ASM and ISO-HAS cells did not differ significantly in response to either bevacizumab 0.25 mg/ml or axitinib 0-250 ng/ml (Fig. 3d, e) . In contrast, both bevacizumab 0.25 mg/ml and axitinib 250 ng/ ml significantly reduced HuDMEC cell migration in the presence of rVEGF 20 ng/ml [mean ± SEM number of migrated HuDMEC cells with rVEGF 20 ng/ml in the absence and presence of bevacizumab 0.25 mg/ml and in the absence and presence of axitinib 250 ng/ml, 23.2 ± 2.6 vs 10.9 ± 0.9 (p = 0.023) and 22.8 ± 2.1 vs 8.3 ± 1.2 (p = 0.013)].
Western blot studies
As the principal receptor mediating VEGF cell signalling, VEGFR2 phosphorylation status in the presence and absence of rVEGF 50 ng/ml was assessed by western blot. In normoxia, there was no evidence of VEGFR2 autophosphorylation in the absence of rVEGF stimulation, however VEGFR2 was phosphorylated in ASM, ISO-HAS and HuDMEC cells in response to stimulation with rVEGF. Western blot studies confirmed that axitinib 50 ng and 250 ng/ml and bevacizumab 0.25 mg/ml inhibited VEGFR2 phosphorylation by rVEGF (Fig. 4a, b) .
As the western blot studies confirmed inhibition of VEGFR2 phosphorylation by VEGF-targeted agents, further western blot studies were performed to assess the levels of phosphorylated ERK (pERK), a key signalling intermediary downstream of VEGFR2, in ASM and ISO-HAS cells. Baseline levels of pERK were established, and a transient increase observed in levels of pERK 5 min after stimulation with rVEGF 50 ng/ml. Baseline and peak pERK levels were reduced, but not absent, in the presence of axitinib 50 ng and 250 ng/ml, and bevacizumab 0.25 mg/ ml (Fig. 4c) . pERK responses were similar in both ASM and ISO-HAS cells.
MEK inhibition
The western blot studies of pERK expression provided a strong rationale for studying ASM and ISO-HAS cell response to MEK inhibition. Response to selumetinib, a selective inhibitor of MEK1/2, was studied across a dose range of 0-2,000 ng/ml. Selumetinib significantly reduced ASM viable cell counts with an estimated IC 50 of 1,750 ng/ ml, but had minimal effects on ISO-HAS cell viability (Fig. 5a ). ASM and ISO-HAS cell response to selumetinib were therefore then studied in cell differentiation assays. Selumetinib reduced ISO-HAS tubule formation in the presence but not in the absence of rVEGF 50 ng/ml (Fig. 5b) , whereas ASM tubule formation was significantly (Fig. 5b) .
Vadimezan VEGF-targeted agents are indirect anti-angiogenic agents that target the vasculature by inhibiting pro-angiogenic signalling. In contrast, vascular-disrupting agents directly target the endothelial cell. As angiosarcomas are tumours of malignant endothelial cells, there was interest in studying their response to vascular-disrupting agents. ASM and ISO-HAS cell responses to the vascular-disrupting agent vadimezan were studied in cell viability assays over a dose range of 0-300 μg/ml. Striking responses were seen in both ASM and ISO-HAS cells, with an IC 50 of 90 and 150 μg/ml, respectively (Fig. 6a) . ASM, ISO-HAS and HuDMEC cell responses to vadimezan 0-100 μg/ml also demonstrated significantly reduced endothelial cell tubule formation in a dose dependent manner in cell differentiation assays (Fig. 6b) .
In vivo, vadimezan rapidly induces apoptosis in tumour endothelial cells and stimulates expression of TNFα. To explore the mechanisms underlying the striking in vitro response to vadimezan, the proportion of apoptotic cells in ASM cells treated with vadimezan, and the expression of TNFα in ASM cell lysates were quantified.
Cell death
The proportions of apoptotic and necrotic cells in ASM cultures incubated in vadimezan 100 μg/ml for 1, 4 and 12 h were measured by flow cytometry using annexin V and propidium iodide staining, respectively. No increase in apoptosis was observed, and there was no difference in the proportion of apoptotic or necrotic cells between control and treated cells at any time point [mean ± SEM 
Discussion
To date the study of angiosarcoma biology has been constrained by its rarity, and by the absence of good pre-clinical models. This is the first study to report on the systematic evaluation of several classes of vascular-targeted agents on two human cutaneous angiosarcoma cell lines in vitro, using non-malignant endothelial cells (HuDMECs) for comparison. The results obtained using ASM and ISO-HAS cell lines were remarkably similar with only minor differences seen. Our data therefore support the continued study of ASM and ISO-HAS cell lines as in vitro models of angiosarcoma. Unfortunately, though consistent with reports from Krump-Konvalinkova et al. [16] , in our hands neither ASM nor ISO-HAS cells formed tumours in vivo.
Consistent with immunohistochemistry studies of human vascular tumours [5] [6] [7] [8] [9] , the protein array studies identified VEGF expression as significantly elevated in ASM , the primary mediator of VEGF signalling on western blotting in normoxia, despite the levels of VEGF secreted into the cell supernatant. We did not assess for activating mutations within the VEGFRs in ASM and ISO-HAS cells, but other studies have suggested the frequency of VEGFR2 mutations in angiosarcoma tumours is low [10, 11] . VEGFR2 was phosphorylated in ASM, ISO-HAS and HuDMEC cells in response to stimulation with rVEGF, however, VEGFR2 phosphorylation did not translate into a functional response in cell differentiation and cell migration assays in ASM and ISO-HAS cells, in contrast to HuDMEC cells.
Despite the absence of response to rVEGF stimulation in functional assays, the increased expression of VEGF by ASM and ISO-HAS cells compared with HuDMECs provided a clear rationale for studying responses to VEGF-targeted agents. ASM and ISO-HAS cell responses to targeted agents in cell viability assays were compared with their responses to doxorubicin and paclitaxel chemotherapy as HuDMEC cells did not flourish in assay conditions. Doxorubicin and paclitaxel chemotherapy are used clinically for the treatment of angiosarcoma, and striking decreases in ASM and ISO-HAS cell viability were observed in response to both drugs. Angiosarcoma tumour response to paclitaxel has been of particular interest clinically as it is an anti-microtubule agent with anti-angiogenic properties, inhibiting endothelial cell differentiation and migration at sub-lethal doses [31] . Promising tumour responses to paclitaxel have been reported in several retrospective series of angiosarcomas [32, 33] , however, the overall response rate in a recent prospective phase II study was disappointing at only 17 % [34] .
In functional assays, only minor responses were observed to the VEGF-targeted agents bevacizumab and axitinib with ASM and ISO-HAS cells, whilst significant responses were seen in functional assays with HuDMECs. As the VEGF ELISA studies showed ASM and ISO-HAS secretion of VEGF was significantly increased in hypoxia, we also studied ASM and ISO-HAS cell responses to bevacizumab 0.25 mg/ml and axitinib 0-250 ng/ml in hypoxic conditions (1 % O 2 ). Responses to VEGF-targeted agents were not amplified in cell viability or cell differentiation assays in hypoxia (data not shown). Together with the absence of cell response to VEGF stimulation, our findings suggest VEGFR2 is not an important driver of angiosarcoma tumour biology. This conclusion is also supported by immunohistochemistry studies demonstrating increased angiosarcoma VEGFR2 expression levels correlates with improved survival, indicating VEGFR2 expression is a marker of endothelial differentiation rather than a pathogenic feature [6, 7] . Whilst the responses to VEGF-targeted agents observed in the current study are disappointing, they are consistent with results from phase II clinical trials that have also reported limited angiosarcoma responses to VEGF-targeted agents [11, 13, 14] . This consistency validates our continued use of these cell lines as potential models of angiosarcoma, and consequently, we assessed ASM and ISO-HAS in vitro responses to other classes of vascular-targeted agents.
The protein array studies show ASM, ISO-HAS and HuDMEC cells express a wide range of pro-angiogenic growth factors, including FGF and PDGF, which have been identified as factors mediating resistance to VEGF-targeted agents in the treatment of tumour angiogenesis [35] . These accessory growth factors may have compensated for VEGF inhibition in ASM and ISO-HAS cells. We thus decided to study cell signalling processes downstream of VEGFR2. Western blot studies of ASM and ISO-HAS cells showed basal activation of the common signalling intermediary ERK, and a recent immunohistochemistry study identified expression of pERK in 12/39 (31 %) angiosarcomas [36] . ASM and ISO-HAS cell responses to the MEK inhibitor selumetinib were therefore studied. Striking responses were induced by MEK inhibition in cell viability and cell differentiation assays with ASM cells, but only in the cell differentiation assays with ISO-HAS. Further studies are warranted to understand these contrasting responses to MEK inhibition and to investigate their clinical significance.
Enhanced responses were also observed to the mTOR inhibitor everolimus in cell viability assays with ASM and ISO-HAS cells. Everolimus reduces VEGF expression but also has broader cellular effects on protein synthesis and cell growth. Several immunohistochemistry studies have highlighted the mTOR pathway as a potential therapeutic target in angiosarcoma, including a study of 68 angiosarcoma specimens reporting high expression of pAkt and pEIF4E in angiosarcomas [5] , and a recent study reporting expression of pS6K and p4eBP1 in 17/40 (42 %) angiosarcomas [36] . The results of SUCCEED, a phase III trial of maintenance therapy with the mTOR inhibitor ridaforolimus for patients with advanced soft tissue sarcoma demonstrated a very small, albeit significant, improvement in progression free survival compared with placebo [37] . Results from this trial specific to angiosarcoma are as yet unreported.
We then studied endothelial cell responses to the vascular-disrupting agent vadimezan. As agents that directly target endothelial cells, there was particular interest in studying responses to this class of drugs. At clinically relevant doses, vadimezan profoundly inhibited ASM and ISO-HAS cell viability and tubule formation. The mechanism underlying this response, however, is unclear. Our data suggest the response was not mediated via initiation of apoptosis, or through an increase in TNFα, both of which are thought important mechanisms in vivo. Interestingly, a recent report proposed vadimezan is also a multi-kinase inhibitor, most prominently of the VEGF receptors [38] . The minor responses we observed to VEGF-targeted agents in ASM and ISO-HAS cells however, suggests VEGF-receptor inhibition is not responsible for the striking responses observed in vitro to vadimezan. Further studies are required to determine the mechanistic and signalling events involved in this response in vivo.
In summary, we have performed a series of studies using two human cutaneous angiosarcoma cell lines, profiling their expression of angiogenesis-related proteins and evaluating their response to vascular-targeted agents in vitro. Our studies have shown that selective targeting of VEGF with bevacizumab or axitinib was less efficacious than treatment with the chemotherapeutic agents paclitaxel and doxorubicin. These responses are consistent with reports from small clinical trials, and suggest ASM and ISO-HAS are a useful model for studying angiosarcoma. Our data shows that further studies are warranted to investigate vascular-disrupting agents, and agents that target common downstream signalling pathways such as mTOR and MEK inhibitors, for the treatment of angiosarcoma.
